Brief: Glass Lewis Joins ISS To Recommend Sesen Bio Stockholders To Approve Pending Merger With Carisma
21/02/2023 14:10
Feb 21 (Reuters) - Sesen Bio Inc SESN.O :
* LEADING INDEPENDENT PROXY ADVISORY FIRM GLASS LEWIS JOINS
ISS IN
RECOMMENDING THAT SESEN BIO STOCKHOLDERS VOTE “FOR” ALL
PROPOSALS TO APPROVE PENDING MERGER WITH CARISMA
Source text for Eikon: ID:nBw30zPhca
Further company coverage: SESN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary